Immunovant

We are aware of fraudulent emails, texts, and job postings claiming to be from Immunovant. These messages often attempt to deceive individuals into believing they have been selected for an interview or job that is not officially posted by our company. Please be aware that: • All legitimate job applications should be submitted through our careers site at immunovant.com/join-us/ • Our HR team does not conduct interviews through Telegram, Google Hangouts, or Microsoft Teams. The majority of our interviews are conducted via Zoom.   •We never ask for bank information or money for IT equipment as part of our recruitment process. To protect yourself: • Always verify job postings on our official careers page.   • Never share personal information unless you’re confident the request is legitimate.   • Contact us directly at careers@immunovant.com if you receive suspicious communication or have concerns. Thank you for helping us maintain a safe and secure job application process.  

Congratulations to the 2024 RareVoice Awards nominees and recipients! These are individuals who champion and amplify the rare disease patient voice every day. Michael Pearlmutter (pictured far right with some of the award recipients), Chief Executive Officer of EveryLife Foundation for Rare Diseases shared, “as a rare disease patient myself, I know the power that comes from the thirty million people living with rare diseases and their caregivers, parents, siblings, friends, and families who give their all - and then find a way to give even more.” Immunovant is proud to partner with the Everylife Foundation for Rare diseases. To learn more about the RareVoice Awards and their other programs visit: https://lnkd.in/gzBeZQV #RareDisease #RareVoice #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #MyastheniaGravis #ThyroidEyeDisease #CIDP

"Further innovation in MG treatment is needed because we know MG is a snowflake disease, affecting people differently, so one therapy may work for one person, but not another. And we all deserve good health and well-being." - Allison Foss, Executive Director, Myasthenia Gravis Association At Immunovant, we are focused on developing therapies that may potentially address the complex and variable needs of people with autoimmune diseases like #MyastheniaGravis. Learn more about our development program in MG: https://lnkd.in/etriCUUd #MGstrong #MGreality #neurology #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare

For people living with #MyastheniaGravis (MG), potential disease deterioration can be especially challenging. In fact, a retrospective study of 1,200 people with MG found that 32% experienced disease exacerbations within one year despite being on treatment; the majority had three or more flare-ups. We believe that people with MG deserve more and better treatment options. At Immunovant, we’re pursuing a patient-focused development approach to potentially help address a range of symptoms across disease stage and severity. Learn more about our work in MG at: https://lnkd.in/etriCUUd #MGStrong #AutoImmuneDisease #RareDisease #PatientFirst #healthcare

"The advice I share with other caregivers is to learn as much as you can! Attend support groups and events, reach out to those living with myasthenia gravis (MG), and share what you learn with others." - Steve, caregiver to wife, Cheryl, who lives with MG (pictured at Myasthenia Gravis Association’s recent annual meeting) MG is unpredictable, and often requires lifestyle modifications for people to engage in everyday activities. For this reason, caregivers play an important role for people living with MG. To learn more about Immunovant’s commitment to #caregivers and those living with #AutoimmuneDisease, visit: https://lnkd.in/e7HwrJUV #NationalFamilyCaregiversMonth #caregiving #MyastheniaGravis #InvisibleDisability #autoimmune #PatientFirst #healthcare

We're kicking off our 5th Annual Thyroid Eye Disease Awareness Week today! Download our free educational resources, including fact sheets and social media graphics in English and Spanish. Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, Provides Educational Resources - Vision Monday Magazine CHICAGO—Prevent Blindness, an eye health and safety nonprofit, has declared November 18-24, 2024, as its fifth annual “Thyroid Eye Disease (TED) Awareness Week.” TED, also known as Graves’ Eye Disease or Graves’ ophthalmopathy, is an autoimmune disease in which the immune system causes inflammation and swelling, and stimulates the production of muscle tissue and fat behind the eye. This year’s TED Awareness Week is supported by Amgen, Immunovant, Tourmaline Bio, Inc. and Viridian Therapeutics, Inc., according to the announcement. Full story at: https://lnkd.in/gCaV9WX4

Managing #MyastheniaGravis (MG) – even while on treatment – can be challenging. A survey of 547 U.S. adults with MG showed that MG symptoms persist despite advances in clinical management. In fact, more than 70% of respondents said their disease wasn’t well-controlled. At Immunovant, we’re developing potentially innovative therapies to help address symptoms across disease stages and severity. Learn more about our efforts to develop a potential new treatment for MG at: https://lnkd.in/etriCUUd #MGStrong #AutoImmuneDisease #RareDisease #PatientFirst #healthcare 

Development updates and financial results for the fiscal quarter ended September 30, 2024 are now available: https://lnkd.in/eF3-RRXP #PressRelease #batoclimab #GravesDisease #FcRn #RheumatoidArthritis #CIDP #ThyroidEyeDisease #MyastheniaGravis #AntithyroidDrugs #thyroid #hyperthyroidism #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare #IMVT 

Larissa Felt, Senior Director, Clinical Operations at Immunovant, recently attended the American Thyroid Association, Inc. (ATA) Annual Meeting. She shared that the event was, “an exciting opportunity to understand the perspectives of both physicians and those living with Graves’ disease.” To learn more about Immunovant’s Graves’ disease program, visit: immunovant.com #2024ATA #GravesDisease #thyroid #hyperthyroidism #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare

Today, we announced that data from the Phase 2a trial of #batoclimab in #GravesDisease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association, Inc. (ATA) Annual Meeting. To read the full #PressRelease, visit: https://lnkd.in/e4DKqhK9 #thyroid #hyperthyroidism #InvisibleDisability #AutoImmuneDisease #autoimmune #PatientFirst #healthcare